The US Patent and Trademark Office (USPTO) has issued notices of allowance for two Mystic Pharmaceuticals patents related to its VersiDoser and VRx2 intranasal delivery platforms. The VersiDoser platform is used for packaging and aerosol delivery of liquid formulations; the VRx2 platform can be used for powder formulations. The patent applications are titled “Unit Dose Drug Delivery Platform” (no. 12/851,524) and “Piercing Device for Drug Delivery Systems” (no. 13/149,584).
Mystic President and CEO Timothy Sullivan commented, “There is a power shift in the pharmaceutical industry from product-oriented to patient-oriented products that deliver better health outcomes. Over the past decade Mystic has innovated packaging and delivery technologies that enable the development of patient-centric pharmaceutical products. These latest innovations further expand our capabilities to enhance the patient experience by making pharmaceutical products that are safer, easier and more convenient to use.”
Read the Mystic press release.
